Dihydroquercetin Nanomicelles Mitigate Hippocampal Apoptosis and Alleviate Autism-Like Behaviors in ASD Rats via the IKK/IKB/NF-κB Signaling Pathway.

Scientists tested a new way to deliver a brain-protective compound called dihydroquercetin to treat autism-like behaviors in rats. They wrapped the compound in tiny particles to help it work better in the body. After 7 days of treatment, rats showed fewer autism-like behaviors and less brain cell damage in the memory area of the brain. This is very early research in animals only.

This preclinical study investigated a novel nanodrug delivery system for dihydroquercetin (DHQ), a neuroprotective compound, in autism spectrum disorder. Researchers encapsulated DHQ in amphiphilic block copolymer nanomicelles (MAN@DHQ) to improve solubility and tested it in ASD rat models over 7 days. The formulation demonstrated efficacy in reducing autism-like behaviors and mitigating hippocampal apoptosis through modulation of the IKK/IκB/NF-κB signaling pathway. Western blot analysis confirmed neuroprotective effects in hippocampal tissue.

While the study presents promising preliminary evidence for a novel pharmacological approach to ASD treatment, it remains in early preclinical stages with limited sample size reporting and unknown study methodology details.

Represents early-stage research into novel neuroprotective approach for ASD. The nanomicelle delivery system shows promise for overcoming solubility barriers of potentially therapeutic compounds. However, extensive preclinical validation and human trials are required before clinical application can be considered.

Study conducted only in animal models with no human data. Sample size not reported and study methodology unclear. Short treatment duration of 7 days limits assessment of long-term effects. No comparison with existing autism treatments provided.

Dihydroquercetin (DHQ), a compound with neuroprotective effects, has shown its potential in a variety of nervous system diseases. However, its mechanism of action in autism spectrum disorder (ASD) remains to be further explored. Due to its poor solubility, the clinical application of DHQ is restricted. In this study, we aimed to improve the solubility of DHQ by constructing a novel nanodrug delivery system.

We utilized the amphiphilic block copolymer MANNOSE-PEG2000-DSPE to encapsulate DHQ, and the resulting formulation was abbreviated as MAN@DHQ. The ASD rats were treated with MAN@DHQ for 7 days. The results of in vivo experiments confirmed that MAN@DHQ could effectively alleviate autism-like behaviors of ASD rats. Western blot results demonstrated that MAN@DHQ mitigate hippocampal apoptosis and ameliorated neuronal damage in the hippocampus of ASD rats via the IKK/IKB/NF-κB signaling pathway.

The therapeutic potential of MAN@DHQ in ASD treatment represents a paradigm-shifting advancement in autism pharmacotherapy and offers promise for clinical interventions for ASD patients.